GlassScriptPhysician profile
Daniel A Sedhom
NPI 1912439308
$6,920.39
in general payments reported to CMS, 2019-2025
32 companies · $3,401 in 2025
The $3,401 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.24 · 2023: $1,096 · 2024: $2,334 · 2025: $3,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,720 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,719.61 |
| Education | $111.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,220.75 | 2022-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,032.95 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $963.77 | 2023-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $451.38 | 2025 | Rezdiffra |
| Lilly USA, LLC | $433.15 | 2023-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $338.70 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Aimmune Therapeutics, INC. | $325.66 | 2023-2025 | Zenpep |
| Qol Medical, LLC | $323.16 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $267.79 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $267.39 | 2024-2025 | Voquezna |
| Pfizer INC. | $241.76 | 2024-2025 | |
| Genzyme Corporation | $216.62 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $173.33 | 2023-2024 | Linzess |
| Celgene Corporation | $115.96 | 2022-2024 | Zeposia |
| Redhill Biopharma INC. | $72.17 | 2022-2023 | Talicia, Aemcolo, Movantik |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $69.46 | 2025 | Iqirvo |
| Celltrion USA INC. | $47.91 | 2024-2025 | Vegzelma |
| Exact Sciences Corporation | $47.54 | 2025 | Cologuard Collection Kit |
| Orphalan INC | $46.79 | 2024-2025 | Cuvrior |
| Laborie Medical Technologies Corp. | $35.61 | 2023 | |
| Merck Sharp & Dohme LLC | $34.96 | 2023-2024 | Dificid, Zerbaxa |
| Organon LLC | $29.06 | 2023-2024 | Renflexis, Hadlima |
| Sanofi Pasteur INC. | $21.90 | 2024 | |
| Sanofi US Services INC. | $18.62 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.45 | 2023 | Dupixent |
| Novo Nordisk INC | $16.46 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $16.09 | 2023 | Rebyota |
| Pacira Pharmaceuticals Incorporated | $15.69 | 2023 | Iovera, Exparel |
| Braintree Laboratories, INC. | $15.43 | 2023 | Sutab |
| Gilead Sciences, INC. | $15.33 | 2025 | |
| Blueprint Medicines Corporation | $13.79 | 2024 | Ayvakit |
| Nestle Healthcare Nutrition INC. | $13.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sedhom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.